Wednesday, 15 January 2025
  
Login

Australia's most trusted
source of pharma news

Wednesday, 15 January 2025
News

Billion-dollar play to stay on top

Posted 13 September 2024 AM

Eli Lilly is looking to cement its place at the top of the obesity food chain with a billion dollar investment into new RNA technology.

The deal is with Swiss biotech Haya Therapeutics, which will receive an upfront payment including an equity investment. It will also be eligible to receive up to a total of $1.5 billion (US$1 billion) in pre-clinical, clinical, and commercial milestone payments, as well as royalties on product sales.

To see the whole article, please login

Popular

Pharmas ready to file new drugs
Four PBS listings kick off 2025
Guess who's scored a new job?
Govt skirts 'contempt' for pharma
Latest Jobs
Pharma in Focus  Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home